Lexaria Bioscience Capital Expenditures

What does Lexaria Bioscience do? Lexaria Bioscience Corp, trading under the ticker LEXX, is a biotechnology company based in Kelowna, Canada, operating within the Health Care sector and Pharmaceuticals industry. The company, which went public via an IPO on October 28, 2009, currently employs five full-time staff members. Lexaria focuses on developing and commercializing its proprietary DehydraTECH drug delivery technology, designed to enhance the bioavailability of active pharmaceutical ingredients (APIs) when taken orally. The technology aims to improve how active molecules enter the bloodstream and has shown potential for enhanced delivery into brain tissue. Lexaria has also applied DehydraTECH to formulations for intraoral and topical administration, demonstrating improved bio-absorption in these delivery methods. The company operates through two business segments: Intellectual Property and Products. It maintains an in-house research laboratory and holds a portfolio of intellectual property, including 35 granted patents and numerous pending patents globally. Lexaria Bioscience Corp is headquartered in Kelowna, British Columbia, and its website is www.lexariabioscience.com. The company has no subsidiaries listed in the provided information, though a reference to a subsidiary named Lexa appears in the source description, which is treated as untrusted and thus excluded from this profile. Lexaria Bioscience is one of the most popular companies on Eulerpool.